 PRINCETON, N.J., June 29, 2021 GLOBE NEWSWIRE -- Oyster Point Pharma, Inc. Nasdaq: OYST, today announced information regarding a key supply chain insight for OC-01 varenicline nasal spray following the announcement that an unrelated manufacturer of varenicline oral tablets has suspended distribution due to impurities discovered in one or more lots of its product. Oyster Point Pharma has not observed any measurable impurities in its OC-01 varenicline nasal spray. 